LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01209650|
Recruitment Status : Approved for marketing
First Posted : September 27, 2010
Last Update Posted : November 10, 2016
The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.
The Compassionate Use Programme will also provide additional safety and efficacy information on BIBW 2992 use.
Named Patient Use (NPU)
|Condition or disease||Intervention/treatment|
|Carcinoma, Non-Small-Cell Lung||Drug: BIBW 2992|
|Study Type :||Expanded Access|
|Official Title:||Expanded Access Program BIBW 2992 for Non Small Cell Lung Cancer ( NSCLC) Last Line Treatment|
Drug: BIBW 2992
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01209650
|Australia, New South Wales|
|1200.47.1 Boehringer Ingelheim Investigational Site|
|North Ryde, New South Wales, Australia|
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim|